TY  - GEN
AU  - Orti, Guillermo
AU  - Sanz, Jaime
AU  - Bermudez, Arancha
AU  - Caballero, Dolores
AU  - Martinez, Carmen
AU  - Sierra, Jorge
AU  - Cabrera Marin, Jose R
AU  - Espigado, Ildefonso
AU  - Solano, Carlos
AU  - Ferra, Christelle
AU  - Garcia-Noblejas, Ana
AU  - Jimenez, Santiago
AU  - Sampol Mayol, Antonia
AU  - Yanez, Lucrecia
AU  - Garcia-Gutierrez, Valentin
AU  - Jesus Pascual, Maria
AU  - Jurado, Manuel
AU  - Moraleda, Jose M
AU  - Valcarcel, David
AU  - Sanz, Miguel A
AU  - Carreras, Enric
AU  - Duarte, Rafael
PY  - 2016
DO  - 10.1016/j.bbmt.2015.11.012
SN  - 1083-8791
UR  - http://hdl.handle.net/20.500.12105/20221
AB  - Allogeneic stem cell transplantation (allo-HCT) represents the most effective immunotherapy for acute myeloid leukemia (AML) and myeloid malignancies. However, disease relapse remains the most common cause of treatment failure. By performing a second...
LA  - eng
PB  - Elsevier
KW  - Second allogeneic stem cell transplantation
KW  - Relapse
KW  - Acute myeloid leukemia
KW  - Myeloid malignancies
KW  - Child
KW  - Disease-Free Survival
KW  - Aged
KW  - Allografts
KW  - Hematopoietic Stem Cell Transplantation
KW  - Adult
KW  - Follow-Up Studies
KW  - Humans
KW  - Child, Preschool
KW  - Adolescent
KW  - Middle Aged
KW  - Male
KW  - Tissue Donors
KW  - Siblings
KW  - Female
KW  - Remission Induction
KW  - Survival Rate
KW  - Hematologic Neoplasms
KW  - Retrospective Studies
TI  - Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Espanol de Trasplante Hematopoyetico
TY  - research article
ER  -